A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to HCC
Related studies linked through entity extraction aliases.
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Status
- NOT_YET_RECRUITING
- Phase
- NA
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- NA
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
- Status
- RECRUITING
- Phase
- PHASE2
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Y-90 Treatment Response Using Transarterial Radioembolization
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
- Status
- RECRUITING
- Phase
- PHASE4
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
- Status
- RECRUITING
- Phase
- PHASE2